Barr ups the ante for Pliva

September 18, 2006

Woodcliff Lake, N.J.-based Barr Pharmaceuticals raised its bid for Pliva to $2.5 billion. Barr's chief rival in the Pliva acquisition is Iceland-based Actavis, which offered $1.85 billion for Pliva, based in Croatia. If Pliva accepts Barr's offer, Barr would become the world's third-largest generic drug manufacturer behind second-place Novartis and No. 1 Teva.

Woodcliff Lake, N.J.-based Barr Pharmaceuticals raised its bid for Pliva to $2.5 billion. Barr's chief rival in the Pliva acquisition is Iceland-based Actavis, which offered $1.85 billion for Pliva, based in Croatia. If Pliva accepts Barr's offer, Barr would become the world's third-largest generic drug manufacturer behind second-place Novartis and No. 1 Teva. Meanwhile, the FDA sent a warning letter to Actavis executives after inspectors found deficiencies in the company's New Jersey manufacturing plant. Actavis said that it has taken actions in response to the warning.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.